Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127451 · ClinicalTrials.gov registry record · Phase 2
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
A Phase 2 study of Stage IV Melanoma and Stage IIIC Melanoma, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 10
- Study locations
NCT01127451 is a Phase 2 study of Stage IV Melanoma and Stage IIIC Melanoma that has completed, run by Eisai. The registered enrollment target is 75 participants, above the 41-participant average among 13 other Stage IV Melanoma trials with a reported enrollment target (83% higher). The trial reports 10 study locations across 9 states.
The verdict
NCT01127451, a Phase 2 study of Stage IV Melanoma and Stage IIIC Melanoma, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.
Conditions Studied
Interventions
- DRUG Denileukin diftitox
Study Locations (10)
California
- - Encinitas
- - Los Angeles
District of Columbia
- - Washington D.C.
Illinois
- - Chicago
Kentucky
- - Louisville
Maryland
- - Baltimore
Michigan
- - Detroit
Nebraska
- - Lincoln
Oregon
- - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2010-06-22 |
| Est. Completion | 2015-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01127451
The ClinicalTrials.gov registry entry for NCT01127451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 41-participant average among 13 other Stage IV Melanoma trials with a reported enrollment target (83% higher). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Denileukin diftitox is the first listed.
NCT01127451 reports 10 study locations spanning 9 distinct geographic areas - top geographies include California, District of Columbia, Illinois.
Frequently Asked Questions
What is clinical trial NCT01127451 about?
NCT01127451 is a clinical study titled "Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma". The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.
What is the current status of trial NCT01127451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2010-06-22. Estimated completion is 2015-04-07.
What conditions does trial NCT01127451 study?
This clinical trial studies the following conditions: Stage IV Melanoma, Stage IIIC Melanoma.
What interventions are being tested in trial NCT01127451?
The interventions under investigation include: Denileukin diftitox (DRUG).
Who is sponsoring clinical trial NCT01127451?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01127451 being conducted?
This trial has 10 study locations across California, District of Columbia, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
COMPLETED · Phase 2
-
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.